GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

EVERSANA has launched a new pharmacovigilance platform to answer the need for advanced analytics and AI in drug safety monitoring and risk management.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Zheng Su discusses the key challenges in clinical trials across the Western and emerging regions, specifically looking at patient recruitment and clinical research. The past decades have witnessed ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review additional materials submitted by the company, suggesting the company may ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...